Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Moderna's stock has been under scrutiny following its recent announcement of a revised financial plan and updates to its mRNA-based pipeline. CEO Stéphane Bancel highlighted the company's success in respiratory vaccines and outlined a focus on five non-respiratory products aiming for approvals by 2027.

However, the biotech company's future prospects have elicited mixed reactions from analysts. Over the past three months, 16 analysts have shared their evaluations, with the average 12-month price target standing at $111.50, a decrease of 18.06% from the previous average.

Trending: This billion-dollar fund has invested in the next big real estate boom, here's how you can join for $10.

This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.